Kestra Medical Technologies (NASDAQ:KMTS) Stock Price Crosses Below 50 Day Moving Average – What’s Next?

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) passed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $27.63 and traded as low as $26.34. Kestra Medical Technologies shares last traded at $26.63, with a volume of 382,493 shares changing hands.

Wall Street Analyst Weigh In

A number of equities analysts have commented on KMTS shares. Royal Bank Of Canada set a $30.00 target price on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. JPMorgan Chase & Co. initiated coverage on Kestra Medical Technologies in a research report on Monday, August 10th. They issued an “overweight” rating and a $30.00 target price on the stock. Piper Sandler restated an “overweight” rating on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Wall Street Zen lowered Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Sunday, November 8th. Finally, BTIG Research reissued a “buy” rating and set a $32.00 target price on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $29.00.

Check Out Our Latest Stock Report on KMTS

Kestra Medical Technologies Stock Down 5.9%

The business’s fifty day moving average price is $27.63 and its 200 day moving average price is $24.17. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of -9.97 and a beta of 0.45.

Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last posted its quarterly earnings data on Monday, September 14th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.14). Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. The company had revenue of $30.97 million for the quarter. On average, equities analysts expect that Kestra Medical Technologies, Ltd. will post -2.45 EPS for the current year.

Insider Buying and Selling at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Brian Webster sold 15,000 shares of the business’s stock in a transaction on Tuesday, October 20th. The stock was sold at an average price of $29.56, for a total value of $443,400.00. Following the completion of the transaction, the insider directly owned 445,215 shares in the company, valued at approximately $13,160,555.40. The trade was a 3.26% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Timothy Moran sold 3,192 shares of the firm’s stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $29.56, for a total transaction of $94,355.52. Following the completion of the sale, the insider directly owned 63,153 shares in the company, valued at $1,866,802.68. This represents a 4.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 251,456 shares of company stock valued at $7,173,746. Corporate insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Kestra Medical Technologies

Several institutional investors and hedge funds have recently modified their holdings of the stock. First Trust Advisors LP lifted its holdings in Kestra Medical Technologies by 352.1% in the 3rd quarter. First Trust Advisors LP now owns 313,012 shares of the company’s stock worth $8,855,000 after buying an additional 243,775 shares in the last quarter. Sei Investments Co. grew its holdings in Kestra Medical Technologies by 22.6% in the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after buying an additional 43,753 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Kestra Medical Technologies by 6.6% in the first quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock valued at $1,844,000 after acquiring an additional 5,731 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Kestra Medical Technologies by 47.2% in the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock worth $1,397,000 after purchasing an additional 22,471 shares during the last quarter. Finally, Corient Private Wealth LP raised its holdings in Kestra Medical Technologies by 284.2% during the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock worth $1,542,000 after buying an additional 44,839 shares during the period.

Kestra Medical Technologies Company Profile

(Get Free Report)

Kestra Medical Technologies is a medical technology company focused on wearable solutions for people at risk of sudden cardiac arrest. Its products combine cardiac monitoring, treatment technology and digital services intended to support patients and their care teams. The company’s flagship product, the ASSURE wearable cardioverter defibrillator, continuously monitors a patient’s heart rhythm and can deliver a treatment shock if it detects a life-threatening arrhythmia. The system also provides alerts and supports remote sharing of patient data with clinicians.

Recommended Stories

Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.